Circulating vascular endothelial growth factor receptor‐3, a pro‐lymphangiogenic and pro‐angiogenic mediator, is decreased in pre‐eclampsia

Objective To compare circulating levels of vascular endothelial growth factor receptor 3 (VEGFR‐3) in women with pregnancy‐induced hypertension (PIH) and in non‐pregnant (NP) and healthy pregnant (HP) women. Methods We conducted a case–control study including PIH (n = 135), HP (n = 68), and NP (n = ...

Full description

Saved in:
Bibliographic Details
Published in:International journal of gynecology and obstetrics 2025-01, Vol.168 (1), p.210-219
Main Authors: Palei, Ana C., Kaihara, Julyane N. S., Cavalli, Ricardo C., Sandrim, Valeria C.
Format: Article
Language:English
Subjects:
Adult
adverse prenatal outcomes
Biomarkers - blood
Brazil
Case-Control Studies
Female
gestational hypertension
Humans
Hypertension, Pregnancy-Induced - blood
Pre-Eclampsia - blood
Pregnancy
pre‐eclampsia
vascular endothelial growth factor receptor
Vascular Endothelial Growth Factor Receptor-3 - blood
VEGFR‐3
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2188-557dd105d311b756f3428961f36133aebf5851b1d80ddc9fe0f965616a7814b83
container_end_page 219
container_issue 1
container_start_page 210
container_title International journal of gynecology and obstetrics
container_volume 168
creator Palei, Ana C.
Kaihara, Julyane N. S.
Cavalli, Ricardo C.
Sandrim, Valeria C.
description Objective To compare circulating levels of vascular endothelial growth factor receptor 3 (VEGFR‐3) in women with pregnancy‐induced hypertension (PIH) and in non‐pregnant (NP) and healthy pregnant (HP) women. Methods We conducted a case–control study including PIH (n = 135), HP (n = 68), and NP (n = 49) women from southeastern Brazil. PIH were diagnosed according to international guidelines, and defined as gestational hypertension (GH, n = 61) or pre‐eclampsia (n = 74). VEGFR‐3 was measured in plasma using ELISA. Results Plasma VEGFR‐3 was increased in HP (1207 pg/mL) compared with NP (133 pg/mL) women; however, PIH (729 pg/mL) patients exhibited lower levels than HP women (both p 
doi_str_mv 10.1002/ijgo.15838
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3089880926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089880926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2188-557dd105d311b756f3428961f36133aebf5851b1d80ddc9fe0f965616a7814b83</originalsourceid><addsrcrecordid>eNp9kc1O4zAUhS3ECMrPhgdAXiJEGN-4SewlqoY_IbEZ1pFj36RGzg92StXdPAISb8iT4NIymtWs7tE9n49sH0JOgF0CY-lP-9z0l5AJLnbIBEQhEz4t5C6ZRJMlRSrTfXIQwjNjDAqAPbLPJTA5hWJC3mfW64VTo-0a-qrCWnuKnenHOTqrHG18vxzntFZ67D31qHGI4uPPG7-gig6-j9Kt2mGuusb2DXZWU9WZrfPPskVjVTx6QW2gBrVHFdBQ20UUI4raqXYIVh2RH7VyAY-385A8Xf_6PbtNHh5v7mZXD4lOQYgkywpjgGWGA1RFltd8mgqZQ81z4FxhVWcigwqMYMZoWSOrZZ7lkKtCwLQS_JCcbXLjVV8WGMaytUGjc6rDfhFKzoQUgsk0j-j5BtW-D8FjXQ7etsqvSmDluoRyXUL5VUKET7e5iyo--i_6_esRgA2wtA5X_4kq7-5vHjehn5N8mDM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089880926</pqid></control><display><type>article</type><title>Circulating vascular endothelial growth factor receptor‐3, a pro‐lymphangiogenic and pro‐angiogenic mediator, is decreased in pre‐eclampsia</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Palei, Ana C. ; Kaihara, Julyane N. S. ; Cavalli, Ricardo C. ; Sandrim, Valeria C.</creator><creatorcontrib>Palei, Ana C. ; Kaihara, Julyane N. S. ; Cavalli, Ricardo C. ; Sandrim, Valeria C.</creatorcontrib><description>Objective To compare circulating levels of vascular endothelial growth factor receptor 3 (VEGFR‐3) in women with pregnancy‐induced hypertension (PIH) and in non‐pregnant (NP) and healthy pregnant (HP) women. Methods We conducted a case–control study including PIH (n = 135), HP (n = 68), and NP (n = 49) women from southeastern Brazil. PIH were diagnosed according to international guidelines, and defined as gestational hypertension (GH, n = 61) or pre‐eclampsia (n = 74). VEGFR‐3 was measured in plasma using ELISA. Results Plasma VEGFR‐3 was increased in HP (1207 pg/mL) compared with NP (133 pg/mL) women; however, PIH (729 pg/mL) patients exhibited lower levels than HP women (both p &lt; 0.05). In addition, plasma VEGFR‐3 was decreased in pre‐eclampsia compared with GH (537 versus 980 pg/mL; p &lt; 0.05). When pre‐eclampsia was classified according to different clinical presentations, plasma VEGFR‐3 was further decreased in the cases identified as pre‐eclampsia with severe features, preterm pre‐eclampsia, and pre‐eclampsia accompanied by small for gestational age (all p &lt; 0.05). Conclusion Our data indicate reduced circulating VEGFR‐3 levels in patients with PIH, specifically in those diagnosed with pre‐eclampsia. Moreover, decreased VEGFR‐3 was associated with adverse clinical outcomes in pre‐eclampsia. These findings expand previous evidence of reduced VEGFR‐3 expression in pre‐eclampsia. Future studies should investigate whether it can be used as a predictive biomarker and/or therapeutic target for pre‐eclampsia. Synopsis Circulating VEGFR‐3 levels were decreased in patients with pregnancy‐induced hypertension, specifically in those with pre‐eclampsia. Decreased VEGFR‐3 was associated with adverse clinical outcomes in pre‐eclampsia.</description><identifier>ISSN: 0020-7292</identifier><identifier>ISSN: 1879-3479</identifier><identifier>EISSN: 1879-3479</identifier><identifier>DOI: 10.1002/ijgo.15838</identifier><identifier>PMID: 39109417</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; adverse prenatal outcomes ; Biomarkers - blood ; Brazil ; Case-Control Studies ; Female ; gestational hypertension ; Humans ; Hypertension, Pregnancy-Induced - blood ; Pre-Eclampsia - blood ; Pregnancy ; pre‐eclampsia ; vascular endothelial growth factor receptor ; Vascular Endothelial Growth Factor Receptor-3 - blood ; VEGFR‐3 ; Young Adult</subject><ispartof>International journal of gynecology and obstetrics, 2025-01, Vol.168 (1), p.210-219</ispartof><rights>2024 International Federation of Gynecology and Obstetrics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2188-557dd105d311b756f3428961f36133aebf5851b1d80ddc9fe0f965616a7814b83</cites><orcidid>0000-0002-2669-5301</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39109417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palei, Ana C.</creatorcontrib><creatorcontrib>Kaihara, Julyane N. S.</creatorcontrib><creatorcontrib>Cavalli, Ricardo C.</creatorcontrib><creatorcontrib>Sandrim, Valeria C.</creatorcontrib><title>Circulating vascular endothelial growth factor receptor‐3, a pro‐lymphangiogenic and pro‐angiogenic mediator, is decreased in pre‐eclampsia</title><title>International journal of gynecology and obstetrics</title><addtitle>Int J Gynaecol Obstet</addtitle><description>Objective To compare circulating levels of vascular endothelial growth factor receptor 3 (VEGFR‐3) in women with pregnancy‐induced hypertension (PIH) and in non‐pregnant (NP) and healthy pregnant (HP) women. Methods We conducted a case–control study including PIH (n = 135), HP (n = 68), and NP (n = 49) women from southeastern Brazil. PIH were diagnosed according to international guidelines, and defined as gestational hypertension (GH, n = 61) or pre‐eclampsia (n = 74). VEGFR‐3 was measured in plasma using ELISA. Results Plasma VEGFR‐3 was increased in HP (1207 pg/mL) compared with NP (133 pg/mL) women; however, PIH (729 pg/mL) patients exhibited lower levels than HP women (both p &lt; 0.05). In addition, plasma VEGFR‐3 was decreased in pre‐eclampsia compared with GH (537 versus 980 pg/mL; p &lt; 0.05). When pre‐eclampsia was classified according to different clinical presentations, plasma VEGFR‐3 was further decreased in the cases identified as pre‐eclampsia with severe features, preterm pre‐eclampsia, and pre‐eclampsia accompanied by small for gestational age (all p &lt; 0.05). Conclusion Our data indicate reduced circulating VEGFR‐3 levels in patients with PIH, specifically in those diagnosed with pre‐eclampsia. Moreover, decreased VEGFR‐3 was associated with adverse clinical outcomes in pre‐eclampsia. These findings expand previous evidence of reduced VEGFR‐3 expression in pre‐eclampsia. Future studies should investigate whether it can be used as a predictive biomarker and/or therapeutic target for pre‐eclampsia. Synopsis Circulating VEGFR‐3 levels were decreased in patients with pregnancy‐induced hypertension, specifically in those with pre‐eclampsia. Decreased VEGFR‐3 was associated with adverse clinical outcomes in pre‐eclampsia.</description><subject>Adult</subject><subject>adverse prenatal outcomes</subject><subject>Biomarkers - blood</subject><subject>Brazil</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>gestational hypertension</subject><subject>Humans</subject><subject>Hypertension, Pregnancy-Induced - blood</subject><subject>Pre-Eclampsia - blood</subject><subject>Pregnancy</subject><subject>pre‐eclampsia</subject><subject>vascular endothelial growth factor receptor</subject><subject>Vascular Endothelial Growth Factor Receptor-3 - blood</subject><subject>VEGFR‐3</subject><subject>Young Adult</subject><issn>0020-7292</issn><issn>1879-3479</issn><issn>1879-3479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9kc1O4zAUhS3ECMrPhgdAXiJEGN-4SewlqoY_IbEZ1pFj36RGzg92StXdPAISb8iT4NIymtWs7tE9n49sH0JOgF0CY-lP-9z0l5AJLnbIBEQhEz4t5C6ZRJMlRSrTfXIQwjNjDAqAPbLPJTA5hWJC3mfW64VTo-0a-qrCWnuKnenHOTqrHG18vxzntFZ67D31qHGI4uPPG7-gig6-j9Kt2mGuusb2DXZWU9WZrfPPskVjVTx6QW2gBrVHFdBQ20UUI4raqXYIVh2RH7VyAY-385A8Xf_6PbtNHh5v7mZXD4lOQYgkywpjgGWGA1RFltd8mgqZQ81z4FxhVWcigwqMYMZoWSOrZZ7lkKtCwLQS_JCcbXLjVV8WGMaytUGjc6rDfhFKzoQUgsk0j-j5BtW-D8FjXQ7etsqvSmDluoRyXUL5VUKET7e5iyo--i_6_esRgA2wtA5X_4kq7-5vHjehn5N8mDM</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Palei, Ana C.</creator><creator>Kaihara, Julyane N. S.</creator><creator>Cavalli, Ricardo C.</creator><creator>Sandrim, Valeria C.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2669-5301</orcidid></search><sort><creationdate>202501</creationdate><title>Circulating vascular endothelial growth factor receptor‐3, a pro‐lymphangiogenic and pro‐angiogenic mediator, is decreased in pre‐eclampsia</title><author>Palei, Ana C. ; Kaihara, Julyane N. S. ; Cavalli, Ricardo C. ; Sandrim, Valeria C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2188-557dd105d311b756f3428961f36133aebf5851b1d80ddc9fe0f965616a7814b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>adverse prenatal outcomes</topic><topic>Biomarkers - blood</topic><topic>Brazil</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>gestational hypertension</topic><topic>Humans</topic><topic>Hypertension, Pregnancy-Induced - blood</topic><topic>Pre-Eclampsia - blood</topic><topic>Pregnancy</topic><topic>pre‐eclampsia</topic><topic>vascular endothelial growth factor receptor</topic><topic>Vascular Endothelial Growth Factor Receptor-3 - blood</topic><topic>VEGFR‐3</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palei, Ana C.</creatorcontrib><creatorcontrib>Kaihara, Julyane N. S.</creatorcontrib><creatorcontrib>Cavalli, Ricardo C.</creatorcontrib><creatorcontrib>Sandrim, Valeria C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palei, Ana C.</au><au>Kaihara, Julyane N. S.</au><au>Cavalli, Ricardo C.</au><au>Sandrim, Valeria C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating vascular endothelial growth factor receptor‐3, a pro‐lymphangiogenic and pro‐angiogenic mediator, is decreased in pre‐eclampsia</atitle><jtitle>International journal of gynecology and obstetrics</jtitle><addtitle>Int J Gynaecol Obstet</addtitle><date>2025-01</date><risdate>2025</risdate><volume>168</volume><issue>1</issue><spage>210</spage><epage>219</epage><pages>210-219</pages><issn>0020-7292</issn><issn>1879-3479</issn><eissn>1879-3479</eissn><abstract>Objective To compare circulating levels of vascular endothelial growth factor receptor 3 (VEGFR‐3) in women with pregnancy‐induced hypertension (PIH) and in non‐pregnant (NP) and healthy pregnant (HP) women. Methods We conducted a case–control study including PIH (n = 135), HP (n = 68), and NP (n = 49) women from southeastern Brazil. PIH were diagnosed according to international guidelines, and defined as gestational hypertension (GH, n = 61) or pre‐eclampsia (n = 74). VEGFR‐3 was measured in plasma using ELISA. Results Plasma VEGFR‐3 was increased in HP (1207 pg/mL) compared with NP (133 pg/mL) women; however, PIH (729 pg/mL) patients exhibited lower levels than HP women (both p &lt; 0.05). In addition, plasma VEGFR‐3 was decreased in pre‐eclampsia compared with GH (537 versus 980 pg/mL; p &lt; 0.05). When pre‐eclampsia was classified according to different clinical presentations, plasma VEGFR‐3 was further decreased in the cases identified as pre‐eclampsia with severe features, preterm pre‐eclampsia, and pre‐eclampsia accompanied by small for gestational age (all p &lt; 0.05). Conclusion Our data indicate reduced circulating VEGFR‐3 levels in patients with PIH, specifically in those diagnosed with pre‐eclampsia. Moreover, decreased VEGFR‐3 was associated with adverse clinical outcomes in pre‐eclampsia. These findings expand previous evidence of reduced VEGFR‐3 expression in pre‐eclampsia. Future studies should investigate whether it can be used as a predictive biomarker and/or therapeutic target for pre‐eclampsia. Synopsis Circulating VEGFR‐3 levels were decreased in patients with pregnancy‐induced hypertension, specifically in those with pre‐eclampsia. Decreased VEGFR‐3 was associated with adverse clinical outcomes in pre‐eclampsia.</abstract><cop>United States</cop><pmid>39109417</pmid><doi>10.1002/ijgo.15838</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2669-5301</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0020-7292
ispartof International journal of gynecology and obstetrics, 2025-01, Vol.168 (1), p.210-219
issn 0020-7292
1879-3479
1879-3479
language eng
recordid cdi_proquest_miscellaneous_3089880926
source Wiley-Blackwell Read & Publish Collection
subjects Adult
adverse prenatal outcomes
Biomarkers - blood
Brazil
Case-Control Studies
Female
gestational hypertension
Humans
Hypertension, Pregnancy-Induced - blood
Pre-Eclampsia - blood
Pregnancy
pre‐eclampsia
vascular endothelial growth factor receptor
Vascular Endothelial Growth Factor Receptor-3 - blood
VEGFR‐3
Young Adult
title Circulating vascular endothelial growth factor receptor‐3, a pro‐lymphangiogenic and pro‐angiogenic mediator, is decreased in pre‐eclampsia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T00%3A23%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20vascular%20endothelial%20growth%20factor%20receptor%E2%80%903,%20a%20pro%E2%80%90lymphangiogenic%20and%20pro%E2%80%90angiogenic%20mediator,%20is%20decreased%20in%20pre%E2%80%90eclampsia&rft.jtitle=International%20journal%20of%20gynecology%20and%20obstetrics&rft.au=Palei,%20Ana%20C.&rft.date=2025-01&rft.volume=168&rft.issue=1&rft.spage=210&rft.epage=219&rft.pages=210-219&rft.issn=0020-7292&rft.eissn=1879-3479&rft_id=info:doi/10.1002/ijgo.15838&rft_dat=%3Cproquest_cross%3E3089880926%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2188-557dd105d311b756f3428961f36133aebf5851b1d80ddc9fe0f965616a7814b83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3089880926&rft_id=info:pmid/39109417&rfr_iscdi=true